mIAP301, an anti-CD47 mAb that blocks the binding between murine CD47 and SIRPα, has been shown to enhance phagocytosis of GL261 glioma cells and glioma stem cells by macrophages and prolonged mouse survival [27,28]. The gene discussed is SIRPA; the disease is central nervous system cancer.